Ardent Health Partners, LLC
NYSE:ARDTMedical - Care Facilities
-$0.14 today
- Market cap
- $2.03B
- Beta
- 0.84
- P/E (TTM)
- 9.4
- EPS (TTM)
- $0.95
Volume 7.27M
Average 0.45M
ARDT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Ardent Health Partners, LLCNYSE: ARDT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $42.99M rose 18.7% year over year, ahead of the +10.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.7% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- Depreciation & amortization amounted to 2.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.7% holds above the trailing-twelve-month pace of +10.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 155.7M USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +3.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 155.7M | +6.4% |
| FY2024 | 2024-12-31 | 146.29M | +3.9% |
| FY2023 | 2023-12-31 | 140.84M | +1.9% |
| FY2022 | 2022-12-31 | 138.17M | +0.7% |
| FY2021 | 2021-12-31 | 137.2M | — |
Depreciation & Amortization vs competitors
How ARDT compares with its peers on the latest reported figures
- ARDT's LTM Mar 2026 depreciation & amortization of $162.49M is the 3rd highest of the 11 companies compared; the peer median is $51.76M.
- Its year-over-year change of +10.4% is the 3rd highest of 11, against a peer median of +3.8%.
- Depreciation & amortization amounts to 2.5% of revenue for ARDT, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $309.19M | -19.9% | +1.5% | 10.5% | |
| LTM Sep 2026 | $201.74M | +10.2% | +17.1% | 5.9% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $162.49M | +10.4% | +4.1% | 2.5% |
| LTM Mar 2026 | $143.16M | -22.5% | -12.0% | 2.6% | |
| LTM Jun 2026 | $54.56M | -5.2% | -7.5% | 3.4% | |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Sep 2026 | $49.13M | +10.2% | +3.5% | 3.1% | |
| LTM Oct 2026 | $25.54M | -9.6% | -10.1% | 1.0% | |
| LTM Sep 2026 | $23.78M | +3.1% | -15.1% | 1.2% | |
| LTM Jun 2026 | $16.71M | +15.1% | +5.3% | 1.1% | |
| LTM Sep 2026 | $16.54M | +4.6% | -5.3% | 9.1% | |
| Peer median (excluding ARDT) | $51.76M | +3.8% | -1.9% | 2.8% | |
Competitors are the stored peer set for ARDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.87B | 5.13B | 5.41B | 5.97B | 6.32B |
| Cost of Revenue | 927.33M | 955.17M | 140.84M | 1.03B | 155.7M |
| Gross Profit | 3.94B | 4.17B | 5.27B | 4.93B | 6.17B |
| Gross Margin | 81.0% | 81.4% | 97.4% | 82.7% | 97.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 3.13B | 3.37B | 3.62B | 3.88B | 1.19B |
| Operating Expenses | 3.51B | 3.96B | 5.04B | 4.53B | 5.84B |
| Depreciation & Amortization | 137.2M | 138.17M | 140.84M | 146.29M | 155.7M |
| EBITDA | 526.93M | 531.7M | 350M | 574.93M | 497.26M |
| EBITDA Margin | 10.8% | 10.4% | 6.5% | 9.6% | 7.9% |
| Operating Income | 436.56M | 217.03M | 229.5M | 405.76M | 325.58M |
| Operating Margin | 9.0% | 4.2% | 4.2% | 6.8% | 5.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 93.83M | 82.05M | 65.43M | 65.58M | 55.2M |
| Other Income / Expenses | (140.68M) | 94.45M | (77.89M) | (42.7M) | (39.23M) |
| Income Before Tax | 295.89M | 311.48M | 151.61M | 363.06M | 286.36M |
| Pre-Tax Margin | 6.1% | 6.1% | 2.8% | 6.1% | 4.5% |
| Income Tax Expense | 51.31M | 46.11M | 22.64M | 63.35M | 56.22M |
| Net Income | 154.26M | 188.91M | 50.29M | 210.34M | 135.81M |
| Net Margin | 3.2% | 3.7% | 0.9% | 3.5% | 2.1% |
| EPS (Basic) | 1.08 | 1.32 | 0.35 | 1.59 | 0.96 |
| EPS (Diluted) | 1.08 | 1.32 | 0.35 | 1.58 | 0.96 |
| Weighted Avg Shares | 143.26M | 143.26M | 143.26M | 132.44M | 140.76M |
| Weighted Avg Shares (Diluted) | 143.26M | 143.26M | 143.26M | 132.75M | 141.45M |
Ardent Health Partners, LLC
NYSE:ARDT
Intrinsic Alpha fair value
Locked
Current Price
$14.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.